<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11720425</article-id><article-id pub-id-type="pmc">2363941</article-id><article-id pub-id-type="pii">6692117</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Taal</surname><given-names>B G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Van Tinteren</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Zoetmulder</surname><given-names>F A N</given-names></name><xref ref-type="aff" rid="aff1">4</xref></contrib><contrib contrib-type="author"><collab>on behalf of the NACCP group<xref ref-type="fn" rid="note1"/></collab></contrib></contrib-group><aff id="aff1"><label>1</label>Departments of Gastroenterology, <label>2</label>Medical Oncology, <label>3</label>Statistics and <label>4</label>Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam</aff><author-notes><fn fn-type="present-address" id="note1"><p>NACCP working party: C. J. H. v.d. Velde MD. Ph.D, Department of Surgery, Leiden University Medical Center; J. Jeekel MD, PhD, Department of Surgery, University Hospital Rotterdam, Dijkzigt Hospital; T. Kok MD, PhD, Department of Medical Oncology, University Hospital Rotterdam, Dijkzigt Hospital; C.W. Taat MD, Ph.D., Department of Surgery, Academic Medical Center, Amsterdam; C.H.N. Veenhof MD, Ph.D, Department of Medical Oncology, Academic Medical Center, Amsterdam; S. Meyer MD, PhD, Department of Surgery, Free University, Amsterdam; Th. Wiggers, MD, PhD, Department of Surgery, Daniel den Hoed Cancer Center, Rotterdam; J.A. Roukema MD, PhD, Department of Surgery, Elisabeth Hospital, Tilburg; M.Eliel MD, Comprehensive Cancer Center Mid and North Netherland, Utrecht; P.W. de Graaf, MD, PhD, Department of Surgery, Reinier de Graff Hospital, Delft; E.J.Th. Rutgers MD, PhD, Department of Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam; O. Dalesio Sc, Department of Biometrics, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam.</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2001</year></pub-date><volume>85</volume><issue>10</issue><fpage>1437</fpage><lpage>1443</lpage><history><date date-type="received"><day>17</day><month>04</month><year>2001</year></date><date date-type="rev-recd"><day>26</day><month>07</month><year>2001</year></date><date date-type="accepted"><day>30</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Based on the first favourable results of adjuvant therapy of 5FU plus levamisole in Dukes C colonic cancer in 1990, we conducted a prospective trial. 1029 patients were randomised to receive one year 5FU plus levamisole or no further treatment following curative surgery for stage II or III colon (<italic>n</italic> = 730) or rectal cancer (<italic>n</italic> = 299). 45&#x00025; were in stage II and 55&#x00025; in stage III. With a median follow-up of 4 years and 9 months a significant reduction in odds of death (25&#x00025;, SD 9&#x00025;, <italic>P</italic> = 0.007) was observed for those with adjuvant treatment (65&#x00025; at 5 year) compared to the observation group (55&#x00025;). Improved relative survival was present in stage III (56&#x00025; vs 44&#x00025;), and in stage II patients (78&#x00025; vs 70&#x00025;). In rectal cancer a non-significant difference in disease-free or overall survival was observed. Distant metastases developed in 76&#x00025;, while local recurrence alone occurred in 14&#x00025;. An early start of adjuvant treatment (&#x0003c; 4 weeks) did not affect results. Compliance to 5FU plus levamisole was 69&#x00025;. Severe toxicity did not occur. In conclusion, one year 5FU plus levamisole was of benefit in stage II and III colonic cancer; in rectal cancer a significant positive effect could not be demonstrated. &#x000a9; 2001 Cancer Research Campaign&#x02002;&#x02002;<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>colonic cancer</kwd><kwd>rectal cancer</kwd><kwd>adjuvant therapy</kwd></kwd-group></article-meta></front></article>


